How Biocon’s Bold Move Transformed India’s Biotech Industry | Kiran Mazumdar-Shaw's Vision

Biocon Biologics

Biocon's Kiran Mazumdar‑shaw Signals Succession Planning; Says Not Stepping Down Yet | CNBC TV18

India’s Pharma Future: Kiran Mazumdar-Shaw on Innovation, GLP-1 Race & Biocon’s Vision

Oncology Biz Continues To Be Strong In The Biosimilar Space: Biocon | CNBC TV18

Biocon vise le leadership mondial de l'insuline alors que les biosimilaires propulsent la prochai...

Biocon Advancing Access to Cancer Care | BBC StoryWorks Rewriting Cancer

Biocon Biologics & Biocon Will See Synergies Such As Supply Chain Procurement: Biocon |#CNBCTV18At26

New Biosimilar Launches To Reflect In FY27e: Biocon Biologics | CNBC TV18

Generics Growth Aided By Other Drugs Besides Liraglutide & API Biz: Biocon | CNBC TV18

From Rejected Job Seeker to India’s Biotech Queen | Biocon Founder Story

Introducing Biocon Electric India's New Range of LED Lights | Illuminate Your World with Innovation

Biocon Bets Big On GLP-1: $1Bn Liraglutide Opportunity In US & EU | Siddharth Mittal | Business News

Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business

How To Get A Life Science / Biotech Internship at Biocon - India's Largest Biopharma company?

Biocon Q2 Results: Biosimilars Power 61% Revenue, US Expansion & New Launches In Pipeline

Biocon To Merge Biocon Biologics; To Issue Shares At ₹405.60 To Biocon Biologics Shareholders

Qu'est-ce que le sémaglutide ? Biocon optimiste quant au potentiel à long terme du sémaglutide | ...

Biocon Q3 Earnings: $9B Opportunity & US Market Share Gains | Yesintek Leads Biosimilar Push!